(2S)-2-amino-6-[(1-amino-4-methylsulfanylbutylidene)amino]hexanoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-2-amino-6-[(1-amino-4-methylsulfanylbutylidene)amino]hexanoic acid
• 化学式: C₁₁H₂₃N₃O₂S
• 分子量: 261.39
• InChiKey: LYNFABGFJYGPMG-VIFPVBQESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.3
• 重原子数：
  17
• 可旋转键数：
  10
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  127
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• COMPOUNDS AND METHODS FOR THE TREATMENT OF ERB B2/NEU POSITIVE DISEASES
  申请人：Bio-Thera Solutions, Ltd. Co.

  公开号：US20140178413A1

  公开（公告）日：2014-06-26

  Disclosed herein are anti-ERB B2/NEU antibodies conjugated with maytansinoid drugs for targeted delivery to disease tissues. Methods relating to the preparation and uses of such drug conjugates to treat ERB B2/NEU positive cells in cancers are provided.

  本文揭示了与马坦西诺伊德药物结合的抗ERB B2/NEU抗体，用于定向传递到疾病组织。提供了与制备和使用此类药物共轭物以治疗癌症中的ERB B2/NEU阳性细胞有关的方法。
• COMPOUNDS AND METHODS FOR THE TREATMENT OF EGFR POSITIVE DISEASES
  申请人：Bio-Thera Solutions, Ltd., Co.

  公开号：US20140178412A1

  公开（公告）日：2014-06-26

  Disclosed herein are anti-EGFR antibodies conjugated with maytansinoid drugs for targeted delivery to disease tissues. Methods related to the preparation and uses of such antibody drug conjugates to treat EGFR positive cells in cancers are provided.

  本文披露了与马替南素类药物结合的抗EGFR抗体，用于靶向输送至疾病组织。提供了与制备和使用这种抗体药物结合物相关的方法，用于治疗癌症中的EGFR阳性细胞。
• COMPOUNDS AND METHODS FOR THE TREATMENT OF CD20 POSITIVE DISEASES
  申请人：BIO-THERA SOLUTIONS, LTD., CO.

  公开号：US20140178411A1

  公开（公告）日：2014-06-26

  Disclosed herein are anti-CD20 antibody conjugated with maytansinoid drugs for targeted delivery to disease tissues. Methods related to the preparation and uses of such antibody drug conjugates to treat CD20 positive cells in cancers are provided.

  本文披露了与马替诺伊德药物结合的抗CD20抗体，用于靶向输送至疾病组织。提供了与制备和使用这种抗体药物结合物相关的方法，用于治疗癌症中的CD20阳性细胞。
• MAYTANSINOID DERIVATIVES
  申请人：Bio-Thera Solutions, Ltd., Co.

  公开号：US20140178415A1

  公开（公告）日：2014-06-26

  Disclosed herein are maytansinoid drug linker derivatives which can be linked to a antigen binding unit (Abu), and maytansinoid drugs linked with an antigen binding unit (Drug-Linker-Antigen binding Unit: D-L-Abu), for targeted delivery to disease tissues. D-L-Abu, D-L-Abu derivatives, and methods relating to the use of such drug conjugates to treat antigen positive cells in cancers and immunological disorders are provided.

  本文披露了可能与抗原结合单位（Abu）连接的美坦西酮药物连接物的衍生物，以及与抗原结合单位连接的美坦西酮药物（药物-连接物-抗原结合单位：D-L-Abu），用于靶向递送至疾病组织。提供了D-L-Abu、D-L-Abu衍生物以及与使用这种药物共轭物治疗癌症和免疫性疾病中的抗原阳性细胞相关的方法。
• [EN] COMPOUNDS AND METHODS FOR THE TREATMENT OF ERB B2/NEU POSITIVE DISEASES<br/>[FR] COMPOSÉS ET PROCÉDÉS PERMETTANT LE TRAITEMENT DE PATHOLOGIES ERB B2/NEU POSITIVES
  申请人：BIO THERA SOLUTIONS LTD

  公开号：WO2014094527A1

  公开（公告）日：2014-06-26

  Disclosed herein are anti-ERB B2/NEU antibodies conjugated with maytansinoid drugs for targeted delivery to disease tissues. Methods relating to the preparation and uses of such drug conjugates to treat ERB B2/NEU positive cells in cancers are provided.

  本文披露了与马替南素类药物结合的抗ERB B2/NEU抗体，用于靶向传递至疾病组织。提供了关于准备和使用这种药物结合物来治疗癌症中的ERB B2/NEU阳性细胞的方法。